Biosceptre, a Cambridge, England, UK-based biotech company, received over £8M in series A funding.
The round, which will be closed on 21st December, 2017, has seen the participation from Tuspark Science and Technology Service Group, the venture arm of Tsinghua University, Beijing, through its investment vehicle, Bluesky Partnership II L.P.
The company intends to use the funds to progress into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7.
Led by CEO Gavin Currie, Biosceptre is a biotechnology company focused on developing cancer treatments targeting nfP2X7. The company’s clinical programs include systemic antibody-based therapeutics and vaccines, intended to treat a range of cancer types. With a phase I trial completed, Biosceptre will be progressing a number of clinical trials across a range of cancer indications. These trials will further advance the establishing of nfP2X7 as a new target for the successful treatment of a range of human cancers.
Sir Greg Winter, founder of Cambridge Antibody Technology and Domantis is acting chairman of the Biosceptre Board of Directors and also chairs the Science Advisory Board.